Innovotech Announces New Director and Grant of Stock Options

Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") is pleased to announce the
appointment of Robert Huizinga to its board of directors. Mr. Huizinga is
currently Vice President, Clinical Affairs of Aurinia Pharmaceuticals Inc.,
formerly Isotechnika Pharma Inc. Prior to this, Mr. Huizinga was at the
University of Alberta Hospitals in the Division of Nephrology & Immunology as a
Nephrology Nurse Clinician and Research Epidemiologist. He holds a Master's
Degree in Medical Sciences - Epidemiology, is a Registered Nurse and has
published many articles with respect to his areas of expertise.


Dr. James Timourian, Chairman of the Board of Directors of Innovotech, states,
"Mr. Huizinga has over twenty years of experience in clinical research. I look
forward to the insights he will bring to the board of directors and believe his
appointment will be a great asset to Innovotech."


As part of Mr. Huizinga's compensation for joining the board of directors, he
will receive 30,000 stock options to purchase common shares of Innovotech at an
exercise price of $0.085 per common share effective October 31, 2013 pursuant to
Innovotech's stock option plan. The stock options expire October 30, 2023.


Mr. Huizinga replaces Dr. Lorne Babiuk who has tendered his resignation from the
Board of Directors due to his many commitments as Vice President Research of the
University of Alberta. Dr. Timourian added, "we sincerely thank Dr. Babiuk for
his very valuable contributions of and consistent support for Innovotech, as
well as for his offer to be available for consultation whenever needed." 


About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms.


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including commercially available
products in a variety of market segments; the MBEC Assay(TM), InnovoSIL(TM),
bioFILM PA(TM), InnovoSCEPT-Human and InnovoSCEPT-Veterinary kits. The MBEC
Assay(TM) is a high throughput biofilm growth device that was recently approved
as an ASTM International standard. InnovoSIL(TM) is a family of silver-based
antimicrobials promising superior performance for medical device coatings,
bioFILM PA(TM) and InnovoSCEPT-Human are the first diagnostic tests to assist
physicians in the selection of the most effective antibiotic treatment for
patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary
tests are designed to determine the most effective antibiotic treatment for
infections for chronic infections in both large and small animals. Agress(R) and
AgreGuard(TM) are unique, environmentally friendly seed treatments and plan
sprays designed to protect crops against both bacterial and fungal infections.
Agress(R) is entering the regulatory approval stage.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Innovotech Inc.
Ken Boutilier
President and CEO
(780) 448-0585 ext. 221
(780) 424-0941 (FAX)
ken.boutilier@innovotech.ca


Connect with us:
Website: www.innovotech.ca
Blog: www.cf-test.ca
Twitter: www.twitter.com/innovotech
Facebook: www.facebook.com/innovotech

Innovotech (TSXV:IOT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024